<DOC>
	<DOCNO>NCT01430156</DOCNO>
	<brief_summary>This blind , placebo-controlled , randomise control trial look effect Heme arginate ( HA ) cadaveric renal transplantation . The investigator know HA upregulate HO-1 , show protective effect animal transplant . The investigator give HA/placebo participant prior transplant repeat day 2 post-transplant compare outcome .</brief_summary>
	<brief_title>Induction HO-1 ; Therapeutic Approach Reduce Ischaemia Reperfusion Injury ( IRI ) Following Deceased Donor Renal Transplantation</brief_title>
	<detailed_description>Patients recruit East Scotland transplant wait list consent arrive hospital . The investigator randomise drug placebo give infusion prior induction transplant . A blood sample take prior infusion renal biopsy take graft implant . These used baseline value . Patients receive standard care unit . The investigator use routine blood test result ( urea creatinine ) determine function graft . The investigator take blood sample 24 hour infusion drug/placebo use determine primary outcome . Blood test take daily renal biopsy take day 5 fulfil secondary objective .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<criteria>patient receive cadaveric single kidney transplant patient standard immunosuppressive regime patient different immunosuppressive patient receive 3rd subsequent kidney transplant patient fully anticoagulated patient unable take Heme Arginate patient unable give inform consent patient combine antiplatelet agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Ischemia-reperfusion injury</keyword>
	<keyword>Heme-oxygenase 1</keyword>
	<keyword>Heme arginate</keyword>
</DOC>